#FENC

@davidegardner.bsky.social

4 days ago

Today's "From the Files" 03-10-26:

Oak & Fence. Pinnacles National Park, CA. 2016 #davidgardnerphotography #lightught #pinnaclesnationalpark #fenc #oak #landscape #green

StockTitan

@stocktitan.net

1 week ago

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute Fennec Pharmaceuticals (NASDAQ:FENC) announced a clinical research collaboration with Tampa General Hospital Cancer Institute to evaluate real-world use of sodium thiosulfate injection (PEDMARK®) for reducing cisplatin-related ototoxicity in adolescent, young adult (AYA) and adult patients with non-metastatic solid tumors.The study will analyze clinical and audiology monitoring data; PEDMARK is approved for pediatric patients aged one month and older and has a NCCN 2A recommendation for AYA patients.

#FENC Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

www.stocktitan.net/news/FENC/fennec-pharmac...

StockTitan

@stocktitan.net

2 months ago

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000

#FENC Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

www.stocktitan.net/news/FENC/southpoint-hol...

StockTitan

@stocktitan.net

3 months ago

Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors Fennec Pharmaceuticals (NASDAQ:FENC) announced that City of Hope will initiate an investigator‑sponsored Phase I study (NCT07218913) to evaluate PEDMARK® (sodium thiosulfate) for prevention of cisplatin‑induced ototoxicity in adult men with stage II‑III metastatic testicular germ cell tumors on Dec 9, 2025. The study tests adding PEDMARK to standard cisplatin chemotherapy to reduce permanent hearing loss. PEDMARK is approved for pediatric localized non‑metastatic solid tumors and has a NCCN 2A recommendation for adolescent and young adult patients. Multiple other investigator‑initiated studies are under review or contracting, with additional details to be shared as programs progress.

#FENC Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

www.stocktitan.net/news/FENC/fennec-pharmac...

StockTitan

@stocktitan.net

3 months ago

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss – Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively) – –

#FENC Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

www.stocktitan.net/news/FENC/fennec-pharmac...

StockTitan

@stocktitan.net

3 months ago

Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor

#FENC Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

www.stocktitan.net/news/FENC/fennec-pharmac...

StockTitan

@stocktitan.net

4 months ago

Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada Fennec Pharmaceuticals (NASDAQ:FENC; TSX:FRX) announced a non-brokered private offering in Canada of common shares at US$7.50 per share to certain existing institutional shareholders for aggregate gross proceeds of up to US$5,025,000. The offering is expected to close on November 17, 2025, subject to subscription agreements, customary closing conditions and receipt of required approvals including the Toronto Stock Exchange.The offering will be made under the listed issuer financing exemption (except Quebec) and the company expects to register any shares in the U.S. under the Securities Act via a prospectus supplement. There is no assurance the offering will complete or the amount raised if completed.

#FENC Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

www.stocktitan.net/news/FENC/fennec-pharmac...

StockTitan

@stocktitan.net

4 months ago

Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares Fennec Pharmaceuticals (NASDAQ:FENC) priced an underwritten public offering of 4,666,667 common shares at $7.50 per share, with gross proceeds expected to be approximately $35,000,000 before discounts and expenses.The underwriters have a 30‑day option to purchase up to an additional 700,000 shares. The offering is expected to close on November 17, 2025, and net proceeds are planned to repay and redeem indebtedness with any remainder for working capital and general corporate purposes.

#FENC Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares

www.stocktitan.net/news/FENC/fennec-pharmac...

StockTitan

@stocktitan.net

4 months ago

Fennec Pharmaceuticals Announces Proposed Offering of Common Shares Fennec Pharmaceuticals (NASDAQ:FENC) announced on November 13, 2025 a proposed underwritten registered public offering of common shares. The company said it will grant the underwriters a 30-day option to purchase up to an additional 15% of the shares sold.Fennec intends to use net proceeds to repurchase and redeem certain indebtedness, with any remaining proceeds for working capital and general corporate purposes. Piper Sandler and Craig-Hallum are joint book-running managers. The offering will be made under a registration statement declared effective by the SEC and the shares will not be offered in Canada.

#FENC Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

www.stocktitan.net/news/FENC/fennec-pharmac...

StockTitan

@stocktitan.net

4 months ago

#FENC Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/FENC/fennec-pharmac...

StockTitan

@stocktitan.net

7 months ago

Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update Fennec Pharmaceuticals (NASDAQ:FENC) reported strong Q2 2025 financial results, with total net revenues of $9.7 million, representing a 33% increase from Q2 2024. The company's flagship product PEDMARK® showed significant growth in both large community practices and academic centers.Key highlights include the addition of PEDMARK® to a large national oncology group's formulary for patients under 40, continued expansion of the Fennec HEARS™ patient support program, and successful initial uptake of PEDMARQSI® in the UK and Germany. The company strengthened its patent portfolio with a new U.S. patent providing protection until 2039.Financial results show operating expenses of $12.4 million and a net loss of $3.2 million for Q2 2025. Cash position stood at $18.7 million as of June 30, 2025. The company expects Japan Clinical Trial (STS-J01) results in H2 2025.

#FENC Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update

www.stocktitan.net/news/FENC/fennec-pharmac...

Brian Wallace

@starg82343.bsky.social

8 months ago

White Horse In The Pasture by Brian Wallace White Horse In The Pasture Photograph by Brian Wallace

pixels.com/featured/whi...
#WhiteHorse #Pasture #Home #Fenc

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

Small-cap stocks with strong volume gains, Tue May 20th - #XNEX #TELA #SBC #QIPT #PANL #MNMD #LAES #KOSS #HOWL #VANI #GAN #FENC #ETNB #CMPS #ARQQ #XYF #VCSA #PGRE #NGL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

Small-cap stocks with strong volume gains, Mon May 19th - #NLSP #MDB #MDCX #ENVB #DVLT #TNGX #QMCO #NVAX #LAES #KTCC #INV #GAN #FTEK #FENC #CXAI #BCLI #AGAE #SOC #PGRE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

10 months ago

Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Fennec Pharmaceuticals (NASDAQ: FENC) reported its Q1 2025 financial results, achieving net product sales of $8.8 million, an 18% increase year-over-year. The company's growth was driven by its refined sales strategy and enhanced PEDMARK® patient support program, Fennec HEARS™. Key highlights include expansion into European markets, with PEDMARQSI® now available in Germany and the UK. Financial metrics show a net loss of $1.17 million in Q1 2025, compared to a net income of $12.84 million in Q1 2024. Cash position stood at $22.6 million as of March 31, 2025. The company continues to focus on growing key PEDMARK® accounts and improving patient support services while expanding its European presence through partnership with Norgine.

#FENC Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/FENC/fennec-pharmac...

StockTitan

@stocktitan.net

1 year ago

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update Fennec Pharmaceuticals (NASDAQ:FENC) reported strong financial results for Q4 and full-year 2024, with PEDMARK® net product sales reaching $29.6 million for the year, a 40% increase from 2023. Q4 2024 sales were $7.9 million, up 13% from Q3.The company ended 2024 with $26.6 million in cash and equivalents, strengthened by a $43 million upfront payment from the Norgine transaction. Fennec completed early repayment of $13 million of convertible debt, saving approximately $1.5 million in annual interest payments.Key developments include PEDMARQSI® commercial launches in the UK and Germany, positive NICE recommendation, and continued momentum in the Adolescent and Young Adult segment. The Japan clinical trial (STS-J01) results are expected in H2 2025. Operating expenses increased year-over-year, with selling and marketing at $18.4 million and G&A at $23.1 million for FY 2024.

#FENC Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/FENC/fennec-pharmac...

StockTitan

@stocktitan.net

1 year ago

Revolutionary Cancer Drug PEDMARQSI Now Available in Germany - $273M Deal Potential Fennec's PEDMARQSI debuts in Germany via Norgine, offering first-ever protection against chemo-induced hearing loss in pediatric cancer patients.

#FENC Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

www.stocktitan.net/news/FENC/fennec-pharmac...

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #FENC ) Learn to Evaluate (FENC) using the Charts

StockTitan

@stocktitan.net

1 year ago

Fennec's PEDMARQSI® Breakthrough: First NHS Treatment for Child Cancer-Related Hearing Loss Groundbreaking therapy shows 50% reduction in cisplatin-induced hearing loss in children. Major NHS approval follows $43M Norgine licensing deal with potential $230M milestone payments.

#FENC Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

www.stocktitan.net/news/FENC/fennec-pharmac...

StockTitan

@stocktitan.net

1 year ago

Fennec Pharma Slashes Debt by $13M, Eliminates $1.5M Annual Interest Expense in Strategic Financial Move Fennec Pharmaceuticals strengthens balance sheet with early debt repayment, reducing convertible debt to $19M while maintaining operational funding through 2026.

#FENC Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

www.stocktitan.net/news/FENC/fennec-pharmac...